BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//A3veen.nl - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:A3veen.nl
X-ORIGINAL-URL:https://www.a3veen.nl
X-WR-CALDESC:Evenementen voor A3veen.nl
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Amsterdam
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260413
DTEND;VALUE=DATE:20260414
DTSTAMP:20260524T175209
CREATED:20260413T034938Z
LAST-MODIFIED:20260413T140110Z
UID:139270-1776038400-1776124799@www.a3veen.nl
SUMMARY:Cancer Calculus - publication
DESCRIPTION:How Merck keeps the price of its blockbuster cancer drug sky-high\, shutting out patients and straining health care systems around the world. \nA yearlong investigation by the International Consortium of Investigative Journalists (ICIJ) has uncovered how Merck & Co. has kept the price of its blockbuster cancer drug Keytruda extraordinarily high while deterring competition. The Cancer Calculus\, an investigation by ICIJ and 47 media partners in 37 countries\, also sheds new light on the strategies that have allowed Merck to widen Keytruda’s use — even in cases where its benefits are more limited and lower dosages may be just as effective. A game changer in cancer treatment\, Keytruda\, known generically as pembrolizumab\, weaponizes a patient’s immune system against cancer cells. The U.S. Food and Drug Administration (FDA) approved it in 2014 to treat advanced melanoma\, the most aggressive form of skin cancer. The FDA has since approved it for 19 types of tumors. ICIJ’s investigation found that Merck’s list prices\, or the initial pre-discount prices\, vary wildly across countries\, ranging from about $850 for a single 100 milligram vial in Indonesia to $6\,015 for the same vial in the U.S. Usually administered via intravenous infusion in 200 mg doses every three weeks or 400 mg doses every six weeks\, treatment can last up to two years — amounting to a staggering $416\,000 according to the drug’s list price in the U.S. — and sometimes longer\, though insurance companies often stop covering the drug after the initial two years. With the cost of prescription drugs continually soaring\, President Donald Trump convened top executives from major drug companies at the White House this past December and promised to lower U.S. drug prices. Among the executives was Robert M. Davis\, head of Merck. All the companies pledged price cuts\, but Merck made no such commitment with Keytruda\, which generated $31.7 billion in 2025 — nearly half the company’s revenue. And 60% of the drug’s sales were in the U.S. Based on hundreds of interviews with oncologists\, cancer patients and their families\, patent experts\, regulators\, pharmaceutical industry insiders and others\, as well as exclusive pricing data and patent analyses\, together with thousands of pages of company presentations\, patent board documents\, lawsuits and corporate and regulatory records\, and more than 1\,000 public records requests in 27 countries\, the Cancer Calculus investigation pulls the curtain back on precisely how Merck maintains its dominance. \nLinks:\nAbout the Cancer Calculus investigation \nThe International Consortium of Investigative Journalists is proud to bring you our latest investigation: The Cancer Calculus
URL:https://www.a3veen.nl/event/cancer-calculus-publication/
LOCATION:Vlaanderen
CATEGORIES:Corruptie,Kanker,Maatschappij,Medisch
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260514
DTEND;VALUE=DATE:20260518
DTSTAMP:20260524T175209
CREATED:20260514T071815Z
LAST-MODIFIED:20260514T173755Z
UID:140533-1778716800-1779062399@www.a3veen.nl
SUMMARY:De 1000 km : Trap mee tegen kanker
DESCRIPTION:De 1000 km is een uniek fietsevenement waarbij teams van één tot acht fietsers vier dagen lang samen trappen tegen kanker\, traditiegetrouw doen de deelnemers dat tijdens het hemelvaartweekend en doorkruisen ze vanuit Mechelen heel Vlaanderen. \nDe uitdaging en het groepsgevoel staan centraal. De 1000 km\, dat is meer dan een sportieve uitdaging. Teams van 1 tot 8 fietsers leggen samen met vele anderen in pelotons 1000 km af\, verspreid over de vier dagen van het hemelvaartweekend. In aanloop naar het evenement zamelt elk team 5500 euro (6000 voor het internationale peloton) startgeld in voor levensbelangrijk kankeronderzoek. \nLinks:\nTrap na trap sterker dan kanker
URL:https://www.a3veen.nl/event/de-1000-km-trap-mee-tegen-kanker/
LOCATION:Vlaanderen\, Vlaanderen\, België
CATEGORIES:Kanker,Medisch
END:VEVENT
END:VCALENDAR